Skip to main content

Kaer NewsHealth

FDA approves generic HIV prevention shot for $40 a year

The FDA granted tentative approval to Dr. Reddy's generic lenacapavir, a $40-per-year HIV prevention shot for 120 low-income countries.

4 min read
FDA approves generic HIV prevention shot for $40 a yearPhoto: STAT

Key points

The FDA tentatively approved Dr. Reddy's generic lenacapavir, a $40-per-year HIV prevention shot for 120 low-income countries.

The US Food and Drug Administration on Monday granted tentative approval to Dr. Reddy's Laboratories for a generic version of lenacapavir, a twice-yearly HIV prevention shot, bringing the drug closer to market in low-income countries. The approval was announced by Dr. Reddy's and Unitaid, a global health initiative. The generic will be available for $40 per person per year in 120 countries, under a pricing agreement announced in September 2025.

The tentative approval is a key step in widening access for dozens of low-income countries, but it does not permit sales in the United States while the branded product remains protected by patent. The designation can help support regulatory and purchasing decisions in eligible countries. Dr. Reddy's is the first of six licensed manufacturers to receive tentative FDA approval.

What the approval changes

Lenacapavir was first developed by US pharmaceutical company Gilead Sciences and approved in June 2025 after proving more than 99.9 per cent effective in large clinical trials. The drug targets HIV's capsid protein, which forms a protective shell around the virus's genetic material. It was named 'Breakthrough of the Year' in 2024 by the journal Science.

The $40-per-year price compares with a US list price of $28,218 a year for branded Yeztugo, before insurance, reported by The Associated Press. The lower figure is an expected price, not confirmation that the drug is already available in every eligible country. The high cost of the branded drug was a major obstacle to its becoming a game-changer against a disease that has killed over 40 million people in four decades.

Gilead Sciences signed non-exclusive, royalty-free licensing agreements in October 2024 with six manufacturers to produce and sell generic lenacapavir in 120 high-incidence, resource-limited countries, subject to regulatory approvals. The company's announcement identifies Dr. Reddy's as one of the licensees. The other five licensed manufacturers had not received FDA approval for their generic versions at the time of the report.

How the price compares

People starting lenacapavir need an HIV test before treatment and another with each injection.

Even before generic availability, more than 125,000 people in 10 early adopter African countries have already started Gilead's lenacapavir, Unitaid's statement said. The twice-yearly injectable can be a more effective way to administer HIV pre-exposure prophylaxis than daily pills, which first won US approval in 2012 but only work if taken consistently. Oral PrEP pills came along in 2012, and before lenacapavir, a PrEP drug called cabotegravir was approved in 2021 requiring shots every two months.

Carmen Perez-Casas, Unitaid's senior strategy lead for HIV and pandemic preparedness, said: 'This is an extraordinary milestone for global health. For too long, people in lower- and middle-income countries have had to wait a decade or more to access breakthrough medicines already available elsewhere.' She added: 'With lenacapavir, we've reduced that gap to little more than a year.'

What happens next

Deepak Sapra, CEO of Pharmaceutical Services and API at Dr. Reddy's, said in a statement: 'This is a moment of immense pride for all of us at Dr. Reddy's.' The generic was granted 'tentative approval' by the FDA under an accelerated pathway that allows sponsors to use existing data, Unitaid said.

Some countries may use the FDA assessment to speed their own regulatory or purchasing decisions, but countries with separate approval procedures may take longer. Initial supplies are expected to reach a few low-income countries by the end of 2026, with wider distribution across eligible countries anticipated in 2027, according to the same report.

Perez-Casas said the real work for lenacapavir was still ahead, in moving from approval to rollout. 'An estimated 1.2 million people acquired HIV last year, even as we now have a medicine offering near-100 per cent protection with just two injections a year,' she said. 'The demand is high, and we cannot afford to lose momentum. Unitaid is already working with governments and partners to support country-led rollouts.'

Frequently asked questions

What is the price of the generic lenacapavir?

The generic will cost $40 per person per year in 120 countries, compared with a US list price of $28,218 a year for branded Yeztugo.

When will the generic lenacapavir be available?

Initial supplies are expected to reach a few low-income countries by the end of 2026, with wider distribution across eligible countries anticipated in 2027.

Why is the FDA approval tentative?

The tentative approval does not permit sales in the US while the branded product remains patent-protected, but it can support regulatory and purchasing decisions in eligible countries.

More from this edition